Precautionary Recall of Ramipril 10mg Batch GR174091
Summary
MHRA has issued a precautionary recall notice to pharmacy and healthcare professionals advising them to stop supplying and return one batch of Ramipril 10mg capsules (batch GR174091) manufactured by Crescent Pharma Limited. The recall follows a patient complaint identifying that sealed cartons of Ramipril 10mg may contain blister strips of Ramipril 5mg due to a manufacturing error during secondary packaging. Patients who received this batch should verify the medication name on the carton matches the blister strips inside and contact their dispensing pharmacy if discrepancy is found.
What changed
MHRA has recalled one batch of Ramipril 10mg capsules (batch GR174091) from Crescent Pharma Limited following a confirmed complaint that sealed cartons may contain Ramipril 5mg blister strips due to a secondary packaging error at the manufacturing site. The error was identified when a patient found the lower dose inside their prescribed medication carton. Both strengths are used to treat hypertension, heart failure, and kidney disease, and the risk to patients of receiving the lower dose temporarily is described as very low.
Pharmacy and healthcare professionals must immediately stop supplying the affected batch and return all remaining stock to suppliers. Patients who received this batch should check whether the blister strips inside their carton match the label and contact their dispensing pharmacy if they do not. Any patient who believes they may have taken the incorrect dose and is experiencing adverse effects should seek medical advice, bringing their medicine leaflet and any remaining tablets to their pharmacy or GP practice.
What to do next
- Pharmacies and healthcare professionals must stop supplying the impacted batch
- Return all remaining stock of batch GR174091 to suppliers
- Patients who received this batch should verify carton contents match blister strip labels and contact their dispensing pharmacy if discrepancies are found
- Report any suspected adverse reactions via the MHRA Yellow Card scheme
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Press release
Precautionary recall of blood pressure medication after manufacturing error
The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
From: Medicines and Healthcare products Regulatory Agency Published 20 April 2026
Crescent Pharma Limited is recalling one batch of Ramipril 10mg capsules as a precautionary measure due to a potential manufacturing error which may mean some cartons contain blister strips of a lower dose, specifically Ramipril 5mg.
This follows a complaint from a patient where it was identified that, inside a sealed carton of Ramipril 10mg capsules, one blister pack of Ramipril 5mg capsules was found. Both product batches were manufactured at the same manufacturing site, and the error appears to have occurred during secondary packaging of the cartons.
The risk to patients of taking the lower dose of this medicine for a limited time is very low.
Dr Alison Cave, MHRA Chief Safety Officer, said:
“If you take Ramipril 10mg, check the packaging for batch number GR174091. The batch number and expiry date information can be found on the outer carton. If you have received this batch, check that the medication name on the carton matches the blister strips inside.
“If the 10 mg carton of Ramipril contains blister strips that are labelled as Ramipril 5mg capsules, contact your dispensing pharmacy. If the carton contains blister strips that are correctly labelled as Ramipril 10mg capsules, you do not need to take further action.”
If you have an impacted pack or previously received this batch and you believe you have taken any Ramipril 5mg capsules that were included in error and are currently experiencing any adverse effects, please seek medical advice. Please take the leaflet that came with your medicine and any remaining tablets with you to your pharmacy or GP practice. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.
If you’ve already taken Ramipril 5mg, please be reassured that there is a very low risk to your health. Both strengths of the medication are used to treat high blood pressure, heart failure, and kidney disease. Any possible impact of a lower dose of Ramipril is expected to be gradual rather than immediate or life threatening.
The MHRA has advised pharmacy and healthcare professionals to stop supplying the impacted batch and return all remaining stock to their suppliers.
Notes to editors
- Please see MHRA’s Class 2 recall for further information and images of the affected product.
- The MHRA is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
- The MHRA is an executive agency of the Department of Health and Social Care.
- For media enquiries, please contact the newscentre@mhra.gov.uk, or call on 020 3080 7651.
Share this page
The following links open in a new tab
Updates to this page
Published 20 April 2026
Named provisions
Related changes
Get daily alerts for MHRA Guidance & Safety
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from MHRA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when MHRA Guidance & Safety publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.